Avastin (bevacizumab)

P3, N=1407, Active, not recruiting, AstraZeneca | Trial completion date: Mar 2028 --> Dec 2026

P2, N=54, Completed, Hospices Civils de Lyon | Unknown status --> Completed | Trial completion date: Oct 2023 --> Jun 2026 | Trial primary completion date: Oct 2023 --> Jun 2026

FAM135B acts as a critical negative regulator of GBM angiogenesis, whose low expression contributes to high tumor angiogenic potential and poor patient prognosis. Mechanistically, HNF4A transcriptionally upregulates FAM135B, which then binds to and stabilizes the IKK complex, inactivating the NF-κB signaling pathway and downregulating IL-6 expression, ultimately inhibiting the JAK/STAT-mediated angiogenic process. FAM135B also remodels the GBM tumor microenvironment by reducing M2 macrophage infiltration. Targeting the HNF4A/FAM135B/NF-κB/IL-6 signaling axis provides a novel and promising therapeutic strategy for GBM anti-angiogenic therapy.

P1/2, N=30, Recruiting, Aveta Biomics, Inc. | Trial completion date: Jan 2026 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Dec 2026

A 40-year-old woman with FIGO stage IVB, BRCA-wildtype HGSOC developed rapid multi-drug resistance following neoadjuvant chemotherapy, optimal cytoreduction, and progression on maintenance olaparib/bevacizumab, gemcitabine, and a USP1 inhibitor. By utilizing topoisomerase I inhibitors, agents like YL205 bypass microtubule-stabilization resistance induced by prior taxane exposure, while "bystander effects" address intratumoral heterogeneity. Longitudinal, biomarker-matched strategies and proactive toxicity management are essential to achieving deep tissue clearance in heavily pretreated HGSOC.

At 15 months following initiation of therapy, the patient remains on maintenance treatment with bevacizumab and pembrolizumab, with no evidence of disease progression to date. This case highlights the potential efficacy of immune checkpoint inhibitor-containing multimodality treatment regimens in the management of advanced cervical SCNEC.

Complete remission was obtained using stereotactic radiotherapy to the brain lesions, followed by platinum-based chemotherapy and maintenance therapy with bevacizumab and olaparib...Their role in this setting remains emerging and primarily supported by limited case reports and small series. Further studies are required to better define their role.

P1/2, N=43, Not yet recruiting, Asso De Recherche Cancers Gynecologiques

P3, N=280, Recruiting, Sun Yat-sen University | Unknown status --> Recruiting | Trial completion date: Dec 2018 --> Dec 2026 | Trial primary completion date: Dec 2017 --> Dec 2026

P2, N=110, Active, not recruiting, University of Oklahoma | Trial primary completion date: Mar 2026 --> Jun 2026

Sequences starting with atezolizumab + bevacizumab + doublet platinum chemotherapy had similar costs and quality-adjusted life-years to sequences starting with pembrolizumab + doublet platinum chemotherapy. Sequences starting with pemetrexed + platinum chemotherapy had the lowest costs but also the lowest total quality-adjusted life-years...46. See the NIHR Funding and Awards website for further award information.

P1/2, N=90, Recruiting, Isofol Medical AB | Trial completion date: Mar 2029 --> Dec 2029 | Trial primary completion date: Mar 2028 --> Nov 2028 | N=60 --> 90